AB0137 THE ASSOCIATION BETWEEN AUTOANTIBODY LEVELS AND THE OUTCOMES OF ANTI-TUMOUR NECROSIS FACTOR ALPHA TREATMENT IN RHEUMATOID ARTHRITIS - A RETROSPECTIVE COHORT STUDY WITH TWO YEARS FOLLOW-UP

Background: In rheumatoid arthritis (RA), autoantibodies namely anticitrullinated protein antibodies (Anti-CCP) have prognostic value, independently predicting radiologic progression. However, the evidence is still controversial about how autoantibody levels change over time and their role in treatments outcomes monitoring disease activity RA. Objectives: This study aimed to characterize changes of (rheumatoid factor (RF) Anti-CCP) explore association between these first anti-tumour necrosis alfa (anti-TNF-α) therapy as biologic agent Methods: An observational retrospective cohort was conducted with two years follow-up. Patients diagnosis RA according American College Rheumatology (ACR) criteria registered on Rheumatic Diseases Portuguese Register (Reuma.pt) who started anti-TNFα (as biologic) 2003 2018 were included. positive (>30 UI/mL) and/or Anti-CCP (>10 U/mL) at visit Demographic, clinical laboratory data obtained by consulting Reuma.pt. Disease Activity Score for 28 joints [DAS28(3v); DAS28(4v); DAS28(3v; C-Reactive Protein (CRP)), DAS28(4v; CRP), delta DAS28(4v)], Health Assessment Questionnaire (HAQ), HAQ, RF assessed baseline, 12 24 months. Continuous variables are presented mean, standard deviation, median, quartile 1 3. Categorical absolute relative frequencies. To examine differences months Wilcoxon test paired samples performed. order correlate DAS28 variables, DAS28(4v), HAQ months, a correlation coefficient, Spearman’s used. Results: A total 116 patients (mean age 50.2±10.4 old; 85.3% female) included median duration 10.5 [5-18.5] follow-up 8 [5-14] years. About 49% FR positivity, 38% only positivity 13% positivity. At 64 (55.2%) had an erosive 50 (43.1%) extra-articular manifestations. Compared baseline (160[74.8-496]), decreased significantly (121[49.1-321.8]) (107.5[43.3-332]) p=0.017 p=0.029, respectively. There no time. No found FR/Anti-CCP different DAS28(4v) delta, Conclusion: We that treated anti-TNF-α biologic, our failed demonstrate (DAS28 DAS28(4v)), HAQ. fact, previous research demonstrated there RA, nonetheless not being static increasing signs inflammation baseline. So, further large needed this considering adjustment confounding inflammatory such number swollen or tender morning stiffness. Disclosure Interests: None declared